Pathological Clotting and Deep Vein Thrombosis in Patients with HIV

Abstract

The number of people infected with human immunodeficiency virus (HIV) is rapidly increasing and the majority of those infected are living in sub-Saharan Africa. Some hallmarks of HIV are inflammation and upregulation of inflammatory markers. A pathological coagulation system may accompany these inflammatory changes and potentially result in venous thromboembolism such as a deep vein thrombosis (DVT). In this review, the authors describe the inflammatory profile in HIV, the treatment regimens currently in place in South Africa, and in particular how HIV affects the hematological system, with specific focus on platelets, red blood cells (RBCs; erythrocytes), and fibrin(ogen). They also discuss the presence of DVT in HIV, focus on screening tests, and suggest a more proactive approach to track the inflammatory profile of HIV patients, by specifically using parameters that might point to pathological coagulation; these should involve platelet, RBC, and fibrin(ogen) analysis. They conclude by suggesting that including coagulation function tests to study the effect of treatment interventions would improve outcomes in these individuals, as it could help in the diagnosis of thromboembolic disease. Furthermore, this approach could streamline treatment strategies due to improved monitoring. A better understanding of hypercoagulability of HIV-infected patients is therefore urgently needed. In conclusion, the authors suggest a panel of pathology tests that should be considered as standard procedures when HIV is present.

Keywords

human immunodeficiency virus - deep vein thrombosis - antiretroviral medication - inflammation - coagulation

Competing Interests

None.

• References

• 1 World Health Organisation. Global health observatory data. Available at: http://www.who.int/gho/hiv/en/ . Accessed January, 2018
• 2 Simon V, Ho DD, Abdool Karim Q. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet 2006; 368 (9534): 489-504
• 3 Dieffenbach CW, Fauci AS. Thirty years of HIV and AIDS: future challenges and opportunities. Ann Intern Med 2011; 154 (11) 766-771
• 4 Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol 2008; 214 (02) 231-241
• 5 Hunt PW. HIV and inflammation: mechanisms and consequences. Curr HIV/AIDS Rep 2012; 9 (02) 139-147
• 6 Weiss L, Haeffner-Cavaillon N, Laude M, Gilquin J, Kazatchkine MD. HIV infection is associated with the spontaneous production of interleukin-1 (IL-1) in vivo and with an abnormal release of IL-1 α in vitro. AIDS 1989; 3 (11) 695-699
• 7 Molina JM, Scadden DT, Byrn R, Dinarello CA, Groopman JE. Production of tumor necrosis factor alpha and interleukin 1 beta by monocytic cells infected with human immunodeficiency virus. J Clin Invest 1989; 84 (03) 733-737
• 8 Emilie D, Peuchmaur M, Maillot MC. , et al. Production of interleukins in human immunodeficiency virus-1-replicating lymph nodes. J Clin Invest 1990; 86 (01) 148-159
• 9 Birx DL, Redfield RR, Tencer K, Fowler A, Burke DS, Tosato G. Induction of interleukin-6 during human immunodeficiency virus infection. Blood 1990; 76 (11) 2303-2310
• 10 Lafeuillade A, Poizot-Martin I, Quilichini R. , et al. Increased interleukin-6 production is associated with disease progression in HIV infection. AIDS 1991; 5 (09) 1139-1140
• 11 World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. HIV/AIDS Programme: Strengthening health services to fight HIV/AIDS. World Health Organization Library Cataloguing-in-Publication Data 2007. :16
• 12 Mocroft A, Vella S, Benfield TL. , et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352 (9142): 1725-1730
• 13 Meintjes G, Maartens G, Boulle A. , et al. Guidelines for antiretroviral therapy in adults by the Southern African HIV Clinicians Society. Southern African Journal of HIV Medicine 2012; 13 (03) 114-134
• 14 Saif MW, Greenberg B. HIV and thrombosis: a review. AIDS Patient Care STDS 2001; 15 (01) 15-24
• 15 Bates CM. HIV medicine: drug side effects and interactions. Postgrad Med J 1996; 72 (843) 30-36
• 16 Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Department of Health and Human Services. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf . Updated October 17, 2017 . Accessed January 18, 2018
• 17 Subbaraman R, Chaguturu SK, Mayer KH, Flanigan TP, Kumarasamy N. Adverse effects of highly active antiretroviral therapy in developing countries. Clin Infect Dis 2007; 45 (08) 1093-1101
• 18 Baker JV, Neuhaus J, Duprez D. , et al; INSIGHT SMART Study Group. Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr 2011; 56 (01) 36-43
• 19 Wolf K, Tsakiris DA, Weber R, Erb P, Battegay M. ; Swiss HIV Cohort Study. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis 2002; 185 (04) 456-462
• 20 Jong E, Meijers JCM, van Gorp ECM, Spek CA, Mulder JW. Markers of inflammation and coagulation indicate a prothrombotic state in HIV-infected patients with long-term use of antiretroviral therapy with or without abacavir. AIDS Res Ther 2010; 7 (09) 9
• 21 Jong E, Louw S, Meijers JCM. , et al. The hemostatic balance in HIV-infected patients with and without antiretroviral therapy: partial restoration with antiretroviral therapy. AIDS Patient Care STDS 2009; 23 (12) 1001-1007
• 22 Kamal AH, Tefferi A, Pruthi RK. How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. Mayo Clin Proc 2007; 82 (07) 864-873
• 23 Poller L. International normalized ratios (INR): the first 20 years. J Thromb Haemost 2004; 2 (06) 849-860
• 24 Franz RC. ROTEM analysis: a significant advance in the field of rotational thrombelastography. S Afr J Surg 2009; 47 (01) 2-6
• 25 van Rooy MJ, Pretorius E. Metabolic syndrome, platelet activation and the development of transient ischemic attack or thromboembolic stroke. Thromb Res 2015; 135 (03) 434-442
• 26 Guyton AC, Hall JE. Human Physiology and Mechanisms of Disease. 6th ed. Philadelphia, PA: W.B. Saunders ; 1997. ;299–300
• 27 Swanepoel AC, Nielsen VG, Pretorius E. Viscoelasticity and ultrastructure in coagulation and inflammation: two diverse techniques, one conclusion. Inflammation 2015; 38 (04) 1707-1726
• 28 Torre D, Pugliese A. Platelets and HIV-1 infection: old and new aspects. Curr HIV Res 2008; 6 (05) 411-418
• 29 Van Der Spuy WJ, Pretorius E. A place for ultrastructural analysis of platelets in cerebral ischemic research. Microsc Res Tech 2013; 76 (08) 795-802
• 30 Metcalf Pate KA, Mankowski JL. HIV and SIV associated thrombocytopenia: an expanding role for platelets in the pathogenesis of HIV. Drug Discov Today Dis Mech 2011; 8 (1-2): e25-e32
• 31 Gresele P, Falcinelli E, Sebastiano M, Baldelli F. Endothelial and platelet function alterations in HIV-infected patients. Thromb Res 2012; 129 (03) 301-308
• 32 Pretorius E, Oberholzer HM, Smit E, Steyn E, Briedenhann S, Franz CR. Ultrastructural changes in platelet aggregates of HIV patients: a scanning electron microscopy study. Ultrastruct Pathol 2008; 32 (03) 75-79
• 33 van Rooy MJ, Pretorius E. Platelet interaction with erythrocytes and propensity to aggregation in essential thrombocythaemia. Lancet 2016; 387 (10024): 1210
• 34 Pretorius E. The role of platelet and fibrin ultrastructure in identifying disease patterns. Pathophysiol Haemost Thromb 2008; 36 (05) 251-258
• 35 Bester J, Matshailwe C, Pretorius E. Simultaneous presence of hypercoagulation and increased clot lysis time due to IL-1β, IL-6 and IL-8. Cytokine 2018; 110: 237-242
• 36 Bester J, Pretorius E. Effects of IL-1β, IL-6 and IL-8 on erythrocytes, platelets and clot viscoelasticity. Sci Rep 2016; 6: 32188
• 37 Page MJ, Bester J, Pretorius E. Interleukin-12 and its procoagulant effect on erythrocytes, platelets and fibrin(ogen): the lesser known side of inflammation. Br J Haematol 2018; 180 (01) 110-117
• 38 Page MJ, Bester J, Pretorius E. The inflammatory effects of TNF-α and complement component 3 on coagulation. Sci Rep 2018; 8 (01) 1812
• 39 Pretorius E, du Plooy JN, Bester J. A comprehensive review on eryptosis. Cell Physiol Biochem 2016; 39 (05) 1977-2000
• 40 Pretorius E, Olumuyiwa-Akeredolu OO, Mbotwe S, Bester J. Erythrocytes and their role as health indicator: using structure in a patient-orientated precision medicine approach. Blood Rev 2016; 30 (04) 263-274
• 41 Pretorius E, Oberholzer HM, van der Spuy WJ, Meiring JH. Age-related changes in fibrin networks and platelets of individuals over 75: a scanning electron microscopy study showing “thrombotic preparedness”. J Thromb Thrombolysis 2010; 29 (03) 271-275
• 42 Pretorius E, du Plooy J, Soma P, Gasparyan AY. An ultrastructural analysis of platelets, erythrocytes, white blood cells, and fibrin network in systemic lupus erythematosus. Rheumatol Int 2014; 34 (07) 1005-1009
• 43 Parinitha S, Kulkarni M. Haematological changes in HIV infection with correlation to CD4 cell count. Australas Med J 2012; 5 (03) 157-162
• 44 Pretorius E, Smit E, Oberholzer HM, Steyn E, Briedenhann S, Franz RC. Investigating the ultrastructure of platelets of HIV patients treated with the immuno-regulator, Canova: a qualitative scanning electron microscopy study. Histol Histopathol 2009; 24 (04) 399-405
• 45 Swanepoel AC, Pretorius E. Erythrocyte-platelet interaction in uncomplicated pregnancy. Microsc Microanal 2014; 20 (06) 1848-1860
• 46 Totora GJ, Grabowski SR. Principles of Anatomy and Physiology. 8th ed. New York, NY: Harper Collins College Publishers ; 1996: 564-570
• 47 Pretorius E, Lipinski B. Differences in morphology of fibrin clots induced with thrombin and ferric ions and its pathophysiological consequences. Heart Lung Circ 2013; 22 (06) 447-449
• 48 Pretorius E, Oberholzer HM, van der Spuy WJ, Swanepoel AC, Soma P. Scanning electron microscopy of fibrin networks in rheumatoid arthritis: a qualitative analysis. Rheumatol Int 2012; 32 (06) 1611-1615
• 49 Pretorius E, Bester J, Vermeulen N. , et al. Poorly controlled type 2 diabetes is accompanied by significant morphological and ultrastructural changes in both erythrocytes and in thrombin-generated fibrin: implications for diagnostics. Cardiovasc Diabetol 2015; 14: 30
• 50 Kell DB, Pretorius E. The simultaneous occurrence of both hypercoagulability and hypofibrinolysis in blood and serum during systemic inflammation, and the roles of iron and fibrin(ogen). Integr Biol 2015; 7 (01) 24-52
• 51 Pretorius E, Swanepoel AC, Oberholzer HM, van der Spuy WJ, Duim W, Wessels PF. A descriptive investigation of the ultrastructure of fibrin networks in thrombo-embolic ischemic stroke. J Thromb Thrombolysis 2011; 31 (04) 507-513
• 52 Pretorius E, Page MJ, Hendricks L, Nkosi NB, Benson SR, Kell DB. Both lipopolysaccharide and lipoteichoic acids potently induce anomalous fibrin amyloid formation: assessment with novel Amytracker™ stains. J R Soc Interface 2018; 15 (139) 20170941
• 53 Litvinov RI, Faizullin DA, Zuev YF, Weisel JW. The α-helix to β-sheet transition in stretched and compressed hydrated fibrin clots. Biophys J 2012; 103 (05) 1020-1027
• 54 Maji SK, Wang L, Greenwald J, Riek R. Structure-activity relationship of amyloid fibrils. FEBS Lett 2009; 583 (16) 2610-2617
• 55 Eisenberg D, Jucker M. The amyloid state of proteins in human diseases. Cell 2012; 148 (06) 1188-1203
• 56 Morris KL, Serpell LC. X-ray fibre diffraction studies of amyloid fibrils. In: Sigurdsson EM, Calero M, Gasset M, eds. Amyloid Proteins: Methods and Protocols, 2nd ed. New York, NY: Humana Press
• 57 Tycko R, Wickner RB. Molecular structures of amyloid and prion fibrils: consensus versus controversy. Acc Chem Res 2013; 46 (07) 1487-1496
• 58 Langkilde AE, Morris KL, Serpell LC, Svergun DI, Vestergaard B. The architecture of amyloid-like peptide fibrils revealed by X-ray scattering, diffraction and electron microscopy. Acta Crystallogr D Biol Crystallogr 2015; 71 (Pt 4): 882-895
• 59 Pretorius E, Page MJ, Engelbrecht L, Ellis GC, Kell DB. Substantial fibrin amyloidogenesis in type 2 diabetes assessed using amyloid-selective fluorescent stains. Cardiovasc Diabetol 2017; 16 (01) 141
• 60 Pretorius E, Mbotwe S, Kell DB. Lipopolysaccharide-binding protein (LBP) reverses the amyloid state of fibrin seen in plasma of type 2 diabetics with cardiovascular co-morbidities. Sci Rep 2017; 7 (01) 9680
• 61 Bester J, Soma P, Kell DB, Pretorius E. Viscoelastic and ultrastructural characteristics of whole blood and plasma in Alzheimer-type dementia, and the possible role of bacterial lipopolysaccharides (LPS). Oncotarget 2015; 6 (34) 35284-35303
• 62 Kell DB, Pretorius E. Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells. Metallomics 2014; 6 (04) 748-773
• 63 Pretorius E, Vermeulen N, Bester J, Lipinski B, Kell DB. A novel method for assessing the role of iron and its functional chelation in fibrin fibril formation: the use of scanning electron microscopy. Toxicol Mech Methods 2013; 23 (05) 352-359
• 64 Pretorius E, Bester J, Vermeulen N, Lipinski B, Gericke GS, Kell DB. Profound morphological changes in the erythrocytes and fibrin networks of patients with hemochromatosis or with hyperferritinemia, and their normalization by iron chelators and other agents. PLoS One 2014; 9 (01) e85271
• 65 Pretorius E, Kell DB. Diagnostic morphology: biophysical indicators for iron-driven inflammatory diseases. Integr Biol 2014; 6 (05) 486-510
• 66 Pretorius E, Mbotwe S, Bester J, Robinson CJ, Kell DB. Acute induction of anomalous and amyloidogenic blood clotting by molecular amplification of highly substoichiometric levels of bacterial lipopolysaccharide. J R Soc Interface 2016; 13 (122) 20160539
• 67 Kell DB, Pretorius E. Proteins behaving badly. Substoichiometric molecular control and amplification of the initiation and nature of amyloid fibril formation: lessons from and for blood clotting. Prog Biophys Mol Biol 2017; 123: 16-41
• 68 Fox EA, Kahn SR. The relationship between inflammation and venous thrombosis. A systematic review of clinical studies. Thromb Haemost 2005; 94 (02) 362-365
• 69 Roumen-Klappe EM, den Heijer M, van Uum SHM, van der Ven-Jongekrijg J, van der Graaf F, Wollersheim H. Inflammatory response in the acute phase of deep vein thrombosis. J Vasc Surg 2002; 35 (04) 701-706
• 70 Folsom AR, Lutsey PL, Astor BC, Cushman M. C-reactive protein and venous thromboembolism. A prospective investigation in the ARIC cohort. Thromb Haemost 2009; 102 (04) 615-619
• 71 O'Brien M. The reciprocal relationship between inflammation and coagulation. Top Companion Anim Med 2012; 27 (02) 46-52
• 72 Petäjä J. Inflammation and coagulation. An overview. Thromb Res 2011; 127 (Suppl. 02) S34-S37
• 73 Baker JV. Chronic HIV disease and activation of the coagulation system. Thromb Res 2013; 132 (05) 495-499
• 74 Funderburg NT, Lederman MM. Coagulation and morbidity in treated HIV infection. Thromb Res 2014; 133 (Suppl. 01) S21-S24
• 75 Peters L, Neuhaus J, Duprez D. , et al; INSIGHT SMART Study Group. Biomarkers of inflammation, coagulation and microbial translocation in HIV/HCV co-infected patients in the SMART study. J Clin Virol 2014; 60 (03) 295-300
• 76 Wohl DA, Arnoczy G, Fichtenbaum CJ. , et al. Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study. Antivir Ther 2014; 19 (02) 141-147
• 77 Graham SM, Mwilu R, Liles WC. Clinical utility of biomarkers of endothelial activation and coagulation for prognosis in HIV infection: a systematic review. Virulence 2013; 4 (06) 564-571
• 78 Nordell AD, McKenna M, Borges AH, Duprez D, Neuhaus J, Neaton JD. ; INSIGHT SMART, ESPRIT Study Groups; SILCAAT Scientific Committee. Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation. J Am Heart Assoc 2014; 3 (03) e000844
• 79 Mooney S, Tracy R, Osler T, Grace C. Elevated biomarkers of inflammation and coagulation in patients with HIV are associated with higher Framingham and VACS Risk Index Scores. PLoS One 2015; 10 (12) e0144312
• 80 Funderburg NT. Markers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patients. Curr Opin HIV AIDS 2014; 9 (01) 80-86
• 81 Young LC, Roediger MP, Grandits G. , et al. Relationship between inflammatory and coagulation biomarkers and cardiac autonomic function in HIV-infected individuals. Biomarkers Med 2014; 8 (09) 1073-1083
• 82 Borges AH, Weitz JI, Collins G. , et al; INSIGHT SILCAAT Scientific Committee. Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease. AIDS 2014; 28 (12) 1791-1796
• 83 Green SA, Smith M, Hasley RB. , et al. Activated platelet-T-cell conjugates in peripheral blood of patients with HIV infection: coupling coagulation/inflammation and T cells. AIDS 2015; 29 (11) 1297-1308
• 84 Baker JV, Huppler Hullsiek K, Bradford RL, Prosser R, Tracy RP, Key NS. Circulating levels of tissue factor microparticle procoagulant activity are reduced with antiretroviral therapy and are associated with persistent inflammation and coagulation activation among HIV-positive patients. J Acquir Immune Defic Syndr 2013; 63 (03) 367-371
• 85 Jackson BS, Mokoena T. Comparison of the therapeutic dose of warfarin in HIV-infected and HIV-uninfected patients: a study of clinical practice. BMJ Open 2017; 7 (02) e013709
• 86 Chalmers RTA, Cross KS, Byrne D, Moores C. Essentials of Vascular Surgery, a Pocket Reference. 2nd ed. Scotland: Vascutek Terumo; 2003: 98-100
• 87 Eyal A, Veller M. HIV and venous thrombotic events. S Afr J Surg 2009; 47 (02) 54-56
• 88 Oh T, Bersten AD, Soni N. Oh's Intensive Care Manual. 5th ed. London, UK: Elsevier Health Science; 2003. ;29:351–352
• 89 Bibas M, Biava G, Antinori A. HIV-associated venous thromboembolism. Mediterr J Hematol Infect Dis 2011; 3 (01) e2011030
• 90 Tripodi A. Liver disease and hemostatic (dys)function. Semin Thromb Hemost 2015; 41 (05) 462-467